The University of Southampton
University of Southampton Institutional Repository

Inhibition of endothelial cell activation by nitric oxide donors

Inhibition of endothelial cell activation by nitric oxide donors
Inhibition of endothelial cell activation by nitric oxide donors
Because nitric oxide (NO) inhibits the expression of endothelial leukocyte adhesion molecules, NO-generating compounds have major therapeutic potential for use outside their classical indications. We report on the in vitro potential antiatherogenicity of two novel cysteine-containing NO donors, SP/W 3672, a fast spontaneous NO releaser, and its prodrug SP/W 5186, which liberates NO after bioactivation. The ability of these two compounds to inhibit monocyte adhesion and surface expression of endothelial adhesion molecules was evaluated and compared with that of other NO donors. SP/W 5186 and SP/W 3672 inhibited the adhesion of U937 monocytes to cultured human endothelial cells more potently than S-nitrosoglutathione (GSNO) or spermine NONOate, whereas nitroglycerin and isosorbide dinitrate were ineffective at comparable concentrations. A similar rank order of potency was found for the inhibition of expression of the adhesion molecules vascular cell adhesion molecule-1, intercellular adhesion molecule-1, and E-selectin as well as for major histocompatibility complex class II antigen expression. Estimated IC(50) values for vascular cell adhesion molecule-1 were >400 microM for SP/W 4744 (control for SP/W 3672 lacking the cysteine moiety), 200 microM for GSNO and spermine NONOate, 80 microM for SP/W 3672, and 50 microM for SP/W 5186. Moreover, SP/W 5186 inhibited VCAM-1 mRNA levels more potently than GSNO. This effect was likely to be transcriptional because mRNA degradation was not affected. In conclusion, SP/W 3672 and SP/W 5186 are novel potent inhibitors of endothelial activation, and this effect appears to relate to their ability to liberate NO for prolonged periods of time, either spontaneously or after conversion to active hydrolytic products.
0022-3565
818-823
Zampolli, Antonella
377f92e5-daf9-49e7-88f6-a5a60340a2b7
Basta, Giuseppina
c1349816-e9f5-4855-bc58-f39831595c2b
Lazzerini, Guido
3481c016-7c84-431b-93ad-5da44b28515a
Feelisch, Martin
8c1b9965-8614-4e85-b2c6-458a2e17eafd
De Caterina, Raffaele
caea839a-f712-4c91-b900-2a37c27381c9
Zampolli, Antonella
377f92e5-daf9-49e7-88f6-a5a60340a2b7
Basta, Giuseppina
c1349816-e9f5-4855-bc58-f39831595c2b
Lazzerini, Guido
3481c016-7c84-431b-93ad-5da44b28515a
Feelisch, Martin
8c1b9965-8614-4e85-b2c6-458a2e17eafd
De Caterina, Raffaele
caea839a-f712-4c91-b900-2a37c27381c9

Zampolli, Antonella, Basta, Giuseppina, Lazzerini, Guido, Feelisch, Martin and De Caterina, Raffaele (2000) Inhibition of endothelial cell activation by nitric oxide donors. The Journal of Pharmacology and Experimental Therapeutics, 295 (2), 818-823. (PMID:11046123)

Record type: Article

Abstract

Because nitric oxide (NO) inhibits the expression of endothelial leukocyte adhesion molecules, NO-generating compounds have major therapeutic potential for use outside their classical indications. We report on the in vitro potential antiatherogenicity of two novel cysteine-containing NO donors, SP/W 3672, a fast spontaneous NO releaser, and its prodrug SP/W 5186, which liberates NO after bioactivation. The ability of these two compounds to inhibit monocyte adhesion and surface expression of endothelial adhesion molecules was evaluated and compared with that of other NO donors. SP/W 5186 and SP/W 3672 inhibited the adhesion of U937 monocytes to cultured human endothelial cells more potently than S-nitrosoglutathione (GSNO) or spermine NONOate, whereas nitroglycerin and isosorbide dinitrate were ineffective at comparable concentrations. A similar rank order of potency was found for the inhibition of expression of the adhesion molecules vascular cell adhesion molecule-1, intercellular adhesion molecule-1, and E-selectin as well as for major histocompatibility complex class II antigen expression. Estimated IC(50) values for vascular cell adhesion molecule-1 were >400 microM for SP/W 4744 (control for SP/W 3672 lacking the cysteine moiety), 200 microM for GSNO and spermine NONOate, 80 microM for SP/W 3672, and 50 microM for SP/W 5186. Moreover, SP/W 5186 inhibited VCAM-1 mRNA levels more potently than GSNO. This effect was likely to be transcriptional because mRNA degradation was not affected. In conclusion, SP/W 3672 and SP/W 5186 are novel potent inhibitors of endothelial activation, and this effect appears to relate to their ability to liberate NO for prolonged periods of time, either spontaneously or after conversion to active hydrolytic products.

This record has no associated files available for download.

More information

Published date: 1 November 2000
Organisations: Clinical & Experimental Sciences

Identifiers

Local EPrints ID: 337872
URI: http://eprints.soton.ac.uk/id/eprint/337872
ISSN: 0022-3565
PURE UUID: 3b00b9a1-d82f-4fa0-a0b5-7f050caefc11
ORCID for Martin Feelisch: ORCID iD orcid.org/0000-0003-2320-1158

Catalogue record

Date deposited: 22 Jun 2012 14:30
Last modified: 08 Jan 2022 03:15

Export record

Contributors

Author: Antonella Zampolli
Author: Giuseppina Basta
Author: Guido Lazzerini
Author: Martin Feelisch ORCID iD
Author: Raffaele De Caterina

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×